VIDEO: Research has made ‘major strides’ in answering key questions in immuno-oncology

CHICAGO — Major strides have been made in determining which patients may benefit or experience toxicity from immunotherapy, Omid Hamid, MD, chief of translational research and immunotherapy and director of melanoma therapeutics at The Angeles Clinic and Research Institute, as well as a HemOnc Today Editorial Board member, said at the ASCO Annual Meeting.

Trends in immuno-oncology research presented at the meeting include advances in combination therapy and increasing response, markers for identifying patients who might experience toxicities, and the personalization of immuno-oncology, Hamid said.

“As I walk through ASCO and get ready to take some things back to my clinic, I find that there are more questions, but we’re beginning to have some of the answers to on how to proceed with choosing the right initial therapy for our patients, and what to do as those patients require the next line of therapy.” – by Kristie L. Kahl

Disclosure: Hamid receives consultant fees from Amgen, Bristol-Myers Squibb, Merck, Novartis and Roche; speaker fees from Amgen, Bristol-Myers Squibb, Genentech and Novartis; and research funding from AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech, Immunocore, Incyte, MedImmune, Merck, Merck Serono, Novartis, Pfizer, Rinat and Roche.